Unanimously Against

Supreme Court Unanimously Rules Against Induced Infringement Claim in Hikma v. Amarin, Clarifying Standards for Generic Drug Labeling

In a unanimous decision, the U.S. Supreme Court ruled that Amarin Pharma failed to state a claim for active inducement of patent infringement against Hikma Pharmaceuticals. The Court clarified that generic drugmakers using "skinny labels" compliant with FDA regulations and industry practice do not induce infringement…